A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
Richard Markus
Helen J. McBride
Monica Ramchandani
Vincent Chow
Jennifer Liu
Dan Mytych
Gary Fanjiang
10.6084/m9.figshare.7998434.v1
https://adisjournals.figshare.com/articles/figure/A_Review_of_the_Totality_of_Evidence_Supporting_the_Development_of_the_First_Adalimumab_Biosimilar_ABP_501/7998434
<p><strong>Provide enhanced digital features for this article</strong><br></p><p>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>adisrapidplus@springer.com</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides</p>
2019-06-04 10:50:53
ABP 501
Adalimumab
Ankylosing spondylitis
Biosimilar
Inflammatory bowel disease
Juvenile idiopathic arthritis
Plaque psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Totality of evidence